SCYNEXIS Recalls BREXAFEMME Nationwide Over Potential Cross Contamination With A Non-Antibacterial ß-Lactam Drug Substance
Portfolio Pulse from Benzinga Newsdesk
SCYNEXIS has issued a nationwide recall of its product BREXAFEMME due to potential cross-contamination with a non-antibacterial ß-Lactam drug substance. The recall could potentially impact the company's revenues and reputation.
September 28, 2023 | 6:34 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The recall of BREXAFEMME by SCYNEXIS could potentially impact the company's revenues and reputation in the short term.
The recall of a product can lead to a decrease in sales and potential regulatory scrutiny, which can negatively impact a company's stock price. In this case, SCYNEXIS's recall of BREXAFEMME could lead to a decrease in revenues and potential damage to the company's reputation, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100